Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II diabetes (T2D) and Wegovy for obesity. Ozempic and Wegovy include the same compound, semaglutide, a GLP-1 receptor agonist. Both medications have experienced rapid demand due to increased prescription rates following label expansions, which have driven up […]
Turning the Page for Obesity Therapies — Addressing Tolerability and Delivery
As scientists and researchers figure out the right balance of GLP-1 to glucagon ratio and a better drug delivery method, we are beginning to turn the page for the many individuals suffering from obesity. The post Turning the Page for Obesity Therapies — Addressing Tolerability and Delivery appeared first on MedCity News.
GLP-1 RAs Protective Against Stroke, Neurodegeneration?
GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs other antidiabetic drugs, a new study shows. Medscape Medical News
From Lab to Landmark Therapy: Meet the Woman Behind GLP-1
Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to have contributed to something that’s helped so many. Medscape
💪 GLP-1s: Diabetes, Weight Loss, and Cancer Reduction
This source explores the impact of semaglutide, a weight loss medication, on muscle mass, glucose regulation, and bone health in adults with obesity. It highlights that muscle loss is a common consequence of weight reduction, particularly with semaglutide, and this loss can negatively affect glucose homeostasis and bone mineral density. The study indicates that older […]
Can Ozempic and other GLP-1 drugs be substitute for work outs? Dr Ambrish Mithal and Raj Ganpath discuss
Endocrinologist Dr Ambrish Mithal, the author of the recently-released book, The Weight Loss Revolution, talks to fitness and nutrition coach, Raj Ganpath, co-founder of The Quad, to decode GLP-1 drugs. Should you take them?
An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP‐1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes
Abstract Advancing therapy in T2DM with injectables, i.e., basal insulin (BI) and GLP-1 receptor agonists (GLP-1RAs) is recommended after the failure of oral glucose lowering agents (OGLAs), BI alone, or BI in combination with OGLAs, especially in persons with, or at high risk of atherosclerotic cardiovascular disease (ASCVD). BI and GLP-1RAs can be administered separately […]
Weight loss drugs like Ozempic may help prevent stroke and reduce brain injury-related complications, studies show
Three studies presented today at the Society of NeuroInterventional Surgery’s (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impact of stroke and related brain injuries or reduce the risk of stroke altogether. These medications, which lower blood sugar and often cause weight loss, are commonly prescribed for type 2 diabetes and obesity and include drugs like semaglutide (Ozempic).
Should We Be Concerned About Glucagon-Like Peptide-1 Receptor Agonists?
In this issue of JAMA Ophthalmology, Shor and colleagues highlight a new potential concern for individuals taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs). They conducted a cohort study using an administrative health database that encompasses all of Ontario, Canada, to examine the risk of progression to new neovascular age-related macular degeneration (nAMD) among patients with […]
GLP-1 Drugs Linked to GERD; Best Upfront Approach for H. Pylori? AI in Colonoscopy
(MedPage Today) — In patients with type 2 diabetes, GLP-1 receptor agonists were associated with a higher risk for gastroesophageal reflux disease (GERD) compared with SGLT-2 inhibitors. (Annals of Internal Medicine) A similar study in Gastro…